Rapport Therapeutics Appoints Pioneering Industry Leader John Maraganore to Board of Directors
Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.
- Rapport Therapeutics, Inc., a clinical-stage biotechnology company leveraging the science of receptor-associated proteins (RAPs) to advance precision neuromedicines, today announced the appointment of John Maraganore, Ph.D., to its Board of Directors.
- View the full release here: https://www.businesswire.com/news/home/20240319245625/en/
“As Rapport sets out to build a leading precision neuroscience company, we are incredibly fortunate to have Dr. Maraganore join our board,” said Abraham Ceesay, Chief Executive Officer of Rapport. - “John is among a few visionary leaders who have guided a new modality from concept to a dynamic platform for drug discovery.
- Dr. Maraganore served as founding CEO of Alnylam from 2002 to 2021, where he led the development of a novel class of medicines, referred to as RNAi therapeutics.